Targeted therapy in the management of non–small-cell lung cancer is discussed.
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL.
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented.
The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed.
Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results.

Results 1 - 5 of 5